drugset
drugset / Trial / NCT05373446

Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study

NCT05373446 ↗

Phase 2 Unknown 72 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Randomized, double-blind, Placebo-Controlled, Phase II Clinical Study to evaluate SSD8432 in combination with Ritonavir in asymptomatic infections or mild/common safety study of efficacy and safety in adult subjects with COVID-19.

Timeline

Start
2022-05-20
Primary completion
2022-10-31
Completion
2023-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject simnotrelvir Small molecule 300 mg —
Subject simnotrelvir Small molecule 750 mg —
Background Ritonavir Other / unclassified 100 mg —

Indications

COVID-19